Press release
Investigation announced for Investors in shares of Annovis Bio, Inc. (NYSE: ANVS)
An investigation for investors in Annovis Bio, Inc. (NYSE: ANVS) shares over potential securities laws violations by Annovis Bio.
Investors who purchased shares of Annovis Bio, Inc. (NYSE: ANVS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Annovis Bio, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Berwyn, PA based Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.
On July 28, 2021, Annovis Bio, Inc. attended the 2021 Alzheimer's Association International Conference and presented new clinical trial data for its lead drug candidate, ANVS401 (Posiphen), that failed to show statistical significance in treating Alzheimer's and Parkinson's patients relative to a placebo.
Shares of Annovis Bio, Inc. (NYSE: ANVS) declined from $132.00 per share on July 23, 2021, to as low as $33.08 per share on July 30, 2021.
Those who purchased shares of Annovis Bio, Inc. (NYSE: ANVS) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Annovis Bio, Inc. (NYSE: ANVS) here
News-ID: 2354131 • Views: …
More Releases from Shareholders Foundation
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd.
Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
More Releases for Annovis
Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerev …
DelveInsight's, "Parkinson's disease - Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Parkinson's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Parkinson's Disease pipeline includes over 130…
Parkinson's Disease Clinical and Non-Clinical Studies, Key Companies, Therapeuti …
DelveInsight's, "Parkinson's Disease- Pipeline Insight, 2025" report provides comprehensive insights about 130+ companies and 150+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 130 prominent companies are actively involved in…
Down Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | AC Immu …
Down Syndrome therapies, such as AEF0217, ACI-24.060, and others, are expected to boost the Down Syndrome Market in the upcoming years.
DelveInsight has launched a new report on "Down Syndrome - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Down Syndrome, historical and forecasted epidemiology as well as the Down Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and…
Lewy Body Disease Pipeline Assessment, 2024 Updates | In-depth Insights Into the …
As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Lewy Body Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
" [https://www.delveinsight.com/report-store/lewy-body-disease-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight outlines a comprehensive assessment of the…
Investigation announced for Long-Term Investors in shares of Annovis Bio, Inc. ( …
An investigation was announced over possible breaches of fiduciary duties by certain directors and officers of Annovis Bio, Inc..
Investors who are current long term investors in Annovis Bio, Inc. (NYSE: ANVS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: ANVS stocks follows a lawsuit filed against Annovis…
Deadline on October 18th coming up in Lawsuit for Investors in shares of Annovis …
A deadline is coming up on October 18, 2021 in the lawsuit filed for certain investors of Annovis Bio, Inc. (NYSE: ANVS) over alleged securities laws violations by Annovis Bio, Inc.
Investors who purchased shares of Annovis Bio, Inc. (NYSE: ANVS) have certain options and there are strict and short deadlines running. Deadline: October 18, 2021. NYSE: ANVS stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
